Who we are

Our existing technology: RTGel^™ is our novel drug delivery platform with the potential to be applied to a variety of unmet medical needs. RTGel is a reverse-thermal hydrogel that is liquid at lower temperatures and converts to gel at body temperature, which offers the opportunity to make local therapy a more effective treatment.

Our promising pipeline: Ranging from nonclinical to phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology.

Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; connecting with this network is a key part of our strategy. We currently have an exclusive worldwide license agreement with Allergan^™ to evaluate RTGel^™ and an early-stage feasibility agreement with Janssen Pharmaceuticals^™ and are continually evaluating new opportunities.